Scarica l'app Stockscreener
2.05
4.59%
0.09
Dopo l'orario di chiusura:
2.05
Precedente Chiudi:
$1.96
Aprire:
$1.96
Volume 24 ore:
131.93K
Relative Volume:
1.83
Capitalizzazione di mercato:
$43.11M
Reddito:
$48.20M
Utile/perdita netta:
$-35.05M
Rapporto P/E:
-1.308
EPS:
-1.5673
Flusso di cassa netto:
$-13.02M
1 W Prestazione:
+6.77%
1M Prestazione:
-2.84%
6M Prestazione:
-1.44%
1 anno Prestazione:
-35.74%
Intervallo 1D:
$1.96
$2.2612
Intervallo di 1 settimana:
$1.80
$2.2612
Portata 52W:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Nome
Celularity Inc
Settore
Industria
Telefono
(908) 768-2170
Indirizzo
170 PARK AVE, FLORHAM PARK
Confronta CELU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
2.05 | 43.11M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-30 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-06 | Downgrade | Truist | Buy → Hold |
| 2022-01-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Celularity Inc Borsa (CELU) Ultime notizie
Two Sigma Investments LP Invests $93,000 in Celularity Inc. (NASDAQ:CELU) - Defense World
Celularity (NASDAQ:CELU) Shares Down 10.4% – Here’s Why - Defense World
# Celularity terminates CFO, appoints interim replacement By Investing.com - Investing.com South Africa
Celularity stock falls after CFO David Beers terminated By Investing.com - Investing.com Nigeria
Celularity stock falls after CFO David Beers terminated - Investing.com Australia
# Celularity terminates CFO, appoints interim replacement - Investing.com Australia
Celularity (CELU) Appoints Interim CFO After Terminating Current CFO | CELU Stock News - GuruFocus
Celularity Names Joseph DosSantos Interim CFO - MarketScreener
Celularity Announces Chief Financial Officer Transition - marketscreener.com
Celularity terminates CFO David Beers - TipRanks
Celularity Announces Sudden CFO Departure, Taps Internal Talent and External Advisory Firm - Stock Titan
Celularity announces publication on advancing ocular surface reconstruction - TipRanks
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology - marketscreener.com
Celularity (CELU) Advances Stem Cell Research with Innovative Bi - GuruFocus
Revolutionary Stem Cell Breakthrough: New Technology Could Transform Eye Disease Treatment - Stock Titan
Celularity Receives Nasdaq Notice Regarding Form 10-Q - The Manila Times
Celularity Inc. Notified by Nasdaq of Non-Compliance with Quarterly Filing Requirements - Nasdaq
Celularity Gets 60 Days to Fix Nasdaq Compliance After Missing Q1 Filing Deadline - Stock Titan
Reklaim Ltd. Reports Record 73% Revenue Growth in Q1 2025 and Launches Subscription Privacy Service - The Globe and Mail
Celularity (NASDAQ:CELU) Trading 7.4% Higher – Here’s Why - Defense World
Celularity extends debt maturity, issues stock to YA II PN By Investing.com - Investing.com India
Celularity extends debt maturity, issues stock to YA II PN - Investing.com Australia
Celularity Extends Note Maturity with YA II PN - TipRanks
Celularity Inc. Advances Placental-Derived Therapies - TipRanks
Celularity (CELU) Reports Significant Revenue Growth in FY24 | C - GuruFocus
Celularity Announces Full Year 2024 Operating and Financial Results - The Manila Times
Celularity Inc. Reports Strong Financial Growth and Increased Revenue for Year Ended December 31, 2024 - Nasdaq
Celularity Inc SEC 10-K Report - TradingView
Nvidia (NVDA) Targets Trillion Dollar Opportunity as Trump Ponders Lifting AI Chip Curbs - The Globe and Mail
Should You Buy PayPal Stock on the Dip in May 2025? - The Globe and Mail
The end of La Niña: Lessons about Plains wheat drought & why spring weather is bearish for most grain markets - The Globe and Mail
Earnings To Watch: Caesars Entertainment (CZR) Reports Q1 Results Tomorrow - The Globe and Mail
Celularity (CELU) Resolves Nasdaq Fee Issue to Avoid Delisting | - GuruFocus
Celularity (NASDAQ:CELU) Stock Price Down 4.7% – Time to Sell? - Defense World
Celularity pays $70,000 fee to Nasdaq following receipt of notice - MSN
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - The Manila Times
Celularity Inc. Faces Potential Delisting from Nasdaq Due to Fee and Filing Delinquencies - Nasdaq
Celularity Given Until May 1 to Address Dual Nasdaq Compliance Issues or Face Delisting - Stock Titan
Celularity faces Nasdaq delisting over late filing By Investing.com - Investing.com India
Celularity faces Nasdaq delisting over late filing - Investing.com
Looking for Exposure to Nvidia Stock? Try These Two ETFs - The Globe and Mail
Markel Group to give a presentation at the beginning of its annual Omaha Brunch - The Globe and Mail
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - The Manila Times
CMS Extends Medicare Coverage for Wound Care Products: Major Win for Skin Substitute Market - Stock Titan
Revolutionary NK Cell Therapy Shows Promise in Cancer Treatment: New Research Reveals - Stock Titan
Celularity Inc Azioni (CELU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celularity Inc Azioni (CELU) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hariri Robert J | Chief Executive Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
3,281 |
0 |
21,482 |
| Haines John R | Senior Exec Vice President |
Apr 13 '25 |
Option Exercise |
0.00 |
1,641 |
0 |
29,698 |
| Beers David C | Chief Financial Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
1,025 |
0 |
18,561 |
| Brigido Stephen | Pres., Functional Regeneration |
Feb 17 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
11,641 |
| Beers David C | Chief Financial Officer |
Feb 17 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
21,932 |
| Haines John R | Senior Exec Vice President |
Feb 17 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
35,092 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):